BRZH Overview

Business Combination Approval: Breeze Holdings Acquisition Corp. has received stockholder approval for its business combination with YD Biopharma Limited, a Taiwan-based biopharmaceutical company, and the new entity will be named YD Bio Limited, expected to trade on Nasdaq under the ticker symbol "YDES."

Company Focus and Future Plans: YD Biopharma is dedicated to developing innovative vaccines and therapeutics for infectious diseases and aims to transform treatment options for various high unmet medical needs, with the transaction expected to close within two weeks.

Class Action Investigation: Monteverde & Associates PC is investigating Breeze Holdings Acquisition Corp. regarding its merger with YD Biopharma Limited, with a shareholder vote scheduled for August 14, 2025.

Firm's Credentials: The firm has a successful track record in recovering millions for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.

Law Firm Overview: Monteverde & Associates PC, recognized as a Top 50 firm in securities class action recovery, is investigating several proposed mergers involving companies like GlycoMimetics, Breeze Holdings, ProAssurance, and Future Vision II, offering free consultations for shareholders.

Contact Information: Shareholders with concerns about the listed companies can reach out to Juan Monteverde, Esq. at Monteverde & Associates PC for more information or assistance regarding their rights and potential claims.

Legal Investigations: Monteverde & Associates PC is investigating several proposed mergers involving Breeze Holdings, Amplify Energy, Paragon 28, and H&E Equipment Services, offering free consultations for shareholders concerned about their rights and potential recoveries.

Firm's Credentials: The firm is recognized as a top class action firm with a successful track record in recovering funds for shareholders, emphasizing the importance of choosing a law firm experienced in class actions.

Proposed Merger: YD Biopharma is set to merge with Breeze Holdings Acquisition Corp., aiming for a Nasdaq listing by early 2025, with an estimated enterprise value of nearly $700 million. The merger will enhance YD Biopharma's capabilities in cancer diagnostics and therapeutics.

Recent Developments: YD Biopharma has secured patents and U.S. authorization for advanced detection technologies for pancreatic and breast cancer, expanding its product offerings and establishing a laboratory dedicated to early cancer detection.

Breeze Holdings Acquisition Corp. Trading Update: Breeze Holdings has received approval to trade on the OTCQX Best Market, with its common stock and warrants now available under the tickers "BRZH" and "BRZHW" as of August 21, 2024.

Business Combination Plans: Following the termination of a business combination with TV Ammo, Inc., Breeze intends to pursue other potential business combinations, with a deadline set by the SEC for completion by December 26, 2024.